Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222115

Enrollment

920

Registered

2013-06-13

Start date

2013-06-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Interventions

investigational material(s) Generic name etc : Ipilimumab(BMS-734016) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-small cell lung cancer (NSCLC) - squamous cell Stage IV or recurrent NSCLC Eastern Cooperative Oncology Group (ECOG) of 0 or 1

Exclusion criteria

Exclusion criteria: Brain Metastases Autoimmune diseases

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS) in subjects who receive one dose of blinded therapy	—

Secondary

Measure	Time frame
Overall Survival Progression Free Survival	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026